ArticleNPJ dementia2026
15 years of longitudinal genetic, clinical, cognitive, imaging, and biochemical measures in DIAN.
Article in NPJ dementia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Age predicts Alzheimer's in Down syndrome better than MRI, plasma, or cognition.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Alzheimer's disease biological domain sub-stratification enhances the precision of functional analyses.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Recommendations for genetic counseling for individuals at risk of autosomal dominant Alzheimer's disease in Latin America.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Obstructive sleep apnea severity, Alzheimer's disease plasma markers, and CSF brain amyloidosis and tau pathology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- The landscape of dementia research, diagnosis, treatment, and care in Latin America.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- Towards an AI biomedical scientist: Accelerating discoveries in neurodegenerative disease.The journal of prevention of Alzheimer's disease · 2025Article
- Immunization targeting diseased proteins in synucleinopathy and tauopathy: insights from clinical trials.Translational neurodegeneration · 2025Review
- Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers.Molecular neurodegeneration · 2025Review
Corrections and comments
- Update of
Authors and funding
41 authors.
Funding
Abstract
The Dominantly Inherited Alzheimer Network Observational Study (DIAN Obs) is a longitudinal, global cohort study investigating brain aging and autosomal dominant Alzheimer's disease (ADAD), a rare monogenic form of Alzheimer's disease (AD). Established in 2008 with support from the National Institute on Aging (NIA), DIAN Obs is designed to collect comprehensive and uniform data with the aim to characterize brain biology and clinical trajectory of individuals at risk for ADAD. Mutations in the amyloid protein precursor (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.